What is it?
**Psilocybe azurescens** is the most potent naturally-occurring psilocybin mushroom known to science, first formally described in 1995 by mycologists Paul Stamets and Jochen Gartz. The species contains up to **1.78% psilocybin** by dry weight—approximately three times more potent than the commonly cultivated *P. cubensis*.
**Taxonomy and Classification**
| Rank | Classification |
|------|----------------|
| Kingdom | Fungi |
| Phylum | Basidiomycota |
| Class | Agaricomycetes |
| Order | Agaricales |
| Family | Hymenogastraceae (formerly Strophariaceae) |
| Genus | Psilocybe |
| Species | P. azurescens |
**Physical Description**
- **Cap (Pileus):** 3–10 cm diameter; conic to convex when young, expanding to broadly convex with age; features a pronounced, persistent broad umbo; chestnut to ochraceous brown to caramel color; strongly bruises blue when damaged
- **Gills:** Ascending, sinuate to adnate; brown, staining indigo-black where injured
- **Stem (Stipe):** 9–20 cm length, 3–6 mm thickness; silky white becoming dingy brown with age; base with coarse white aerial tufts of mycelium with azure tones
- **Spore print:** Dark purplish brown to purplish black
- **Bluing reaction:** Intense and rapid—the species name "azurescens" references this azure color
**Geographic Distribution**
P. azurescens has a very restricted natural distribution in the Pacific Northwest USA:
- **Oregon:** Columbia River Delta, Hammond (type location), Astoria, Tillamook, extends south to Depoe Bay
- **Washington:** Long Beach to Westport, Grays Harbor County, Ilwaco
**Why Exercise Extreme Caution**
P. azurescens is generally **NOT recommended for beginners** due to:
1. **Extreme potency:** Up to 1.8% psilocybin (nearly 3× P. cubensis); small measurement errors lead to significantly different effects
2. **Potency variability:** Alkaloid content varies significantly; younger mushrooms typically contain higher concentrations
3. **Wood lover's paralysis risk:** Temporary paralysis/weakness occurring 4-6 hours post-consumption, lasting up to 24 hours
4. **Complex alkaloid profile:** High baeocystin content may produce less predictable effects
**If used for microdosing:** Start with extremely low doses (30-50mg dried), use precision scales (0.001g minimum), homogenize material thoroughly.
🚨 Important Warnings
Please read all warnings carefully before use.
WOOD LOVER'S PARALYSIS (WLP): P. azurescens is strongly associated with temporary paralysis or muscle weakness lasting up to 24 hours. Symptoms include numbness, loss of motor control, facial muscle paralysis. The causative compound is unknown. This effect does NOT occur with P. cubensis.
NOT FOR BEGINNERS: Due to extreme potency, high variability between specimens, narrow therapeutic window, and wood lover's paralysis risk, P. azurescens is NOT recommended for microdosing beginners. Consider P. cubensis or other better-characterized species first.
EXTREME POTENCY: P. azurescens contains up to 1.78% psilocybin—approximately 3× more potent than P. cubensis. Use only 30-50mg for microdosing (vs. 100-150mg for P. cubensis). Milligram-accurate scales (0.001g) are ESSENTIAL.
⚠️ Interactions & Combinations
Important information about drug interactions and combinations. Always consult a physician before combining.
Lithium (Mood Stabilizer)
Dangerous - Seizure Risk
Multiple reports document dangerous interactions causing seizures, bad trips, and medical emergencies. Nayak et al. (2021) analyzed 62 online reports: 47% involved seizures, 39% required medical attention. Mechanism unknown but both substances increase cortical excitability. ABSOLUTE CONTRAINDICATION.
MAOIs (Monoamine Oxidase Inhibitors)
Serotonin Syndrome Risk
MAOIs inhibit enzymes that break down psilocin, leading to higher and prolonged plasma levels. Combined with reduced serotonin degradation, this can cause potentially fatal serotonin syndrome (hyperthermia, rigidity, seizures). Allow minimum 2 weeks washout after irreversible MAOIs. ABSOLUTE CONTRAINDICATION.
SSRIs (Selective Serotonin Reuptake Inhibitors)
Blunted/Reduced Effects
Chronic SSRI use causes downregulation of 5-HT2A receptors. 47% of SSRI users report weaker effects. Blunting effect may persist 3-6 months after discontinuation. Serotonin syndrome risk appears LOW with psilocybin (unlike MDMA). DO NOT self-taper—SSRI withdrawal can be severe.
Antipsychotics
Blocks/Abolishes Effects
Atypical antipsychotics have high affinity for 5-HT2A receptors as antagonists. RCTs show 98-99% blocking with risperidone 1mg. Haloperidol (typical antipsychotic) does NOT block visual effects but increases anxiety—NOT recommended as "trip terminator."
Tricyclic Antidepressants
Potentially Increased/Intensified Effects (Unpredictable)
Unlike SSRIs, TCAs may intensify psychedelic experiences due to postsynaptic receptor sensitization. Clomipramine poses highest serotonin syndrome risk. Taper 2+ weeks under medical supervision before use.
💊 Dosage Guidelines
Typical dosage ranges from sub-perceptual microdoses to full psychoactive doses
Microdose
0.04 g
Sub-perceptual
Threshold
0.08 g
First noticeable effects
Moderate
0.8 g
Full effects
Strong
1.5 g
Intense experience
🧪 Preparation
Preparation methods and handling tips for accurate dosing.
**Critical Warning for P. azurescens**
P. azurescens requires **0.001g (milligram) scale accuracy**—standard 0.1g scales are NOT sufficient. A small measurement error has significantly larger consequences than with P. cubensis.
---
**Method 1: Precision Capsule Method** (Recommended)
*Difficulty: 2/5 | Best for: Most consistent, accurate microdosing*
**Required:** Precision scale (0.001g), coffee grinder, empty capsules (size 0 or 00), capsule filling machine (optional), nitrile gloves, airtight container with desiccant.
**Steps:**
1. Ensure complete drying (cracker-crisp)
2. Weigh total material before grinding
3. Grind to fine, uniform powder (homogenizes potency variation)
4. **P. azurescens dose: 30-50mg (0.030-0.050g)**
5. Tare scale with empty capsule; add powder to target weight
6. Fill and seal capsules; label with date, species, dosage
**Storage:** Airtight container with desiccant, cool/dark/dry location
**Shelf life:** 6-12 months; potency degrades faster once ground
**Example:** 1 gram dried P. azurescens = approximately 25-33 microdoses at 30-40mg each
---
**Method 2: Honey Infusion ("Blue Honey")**
*Difficulty: 3/5 | Best for: Long-term storage, masking taste*
**WARNING:** Makes precise dosing EXTREMELY DIFFICULT. Due to P. azurescens' potency, the capsule method is strongly preferred.
**Steps:**
1. Weigh total dried powder; calculate total doses
2. Add to raw organic honey in sterilized jar
3. Stir thoroughly; store sealed in cool, dark place
4. Turn/shake every few days for 2-3 weeks
5. Weigh honey portions (not volume) for dosing
**Critical note:** Uneven powder distribution makes consistent dosing nearly impossible for high-potency species. Prepare very dilute mixtures and start extremely low.
📋 Microdosing Protocols
Recommended protocols and regimens for microdosing this substance.
Fadiman Protocol (adapted for P. azurescens)
Dosage:
- Dried Mushrooms: 30-50 mg (0,030-0,050 g) — přibližně 1/3 dávky P. cubensis
Schedule:
Day 1: microdose, Day 2-3: off, repeat
The most widely used microdosing protocol, adapted for P. azurescens extreme potency. Requires milligram-accurate scales (0.001g minimum, 0.001g preferred).
Detailed Schedule:
- Day 1: Take microdose in the morning on a commitment-free day
- Day 2: Transition day - observe afterglow effects
- Day 3: Normal day - reset/baseline
- Day 4: Repeat with microdose
Stamets Stack (adapted for P. azurescens)
Dosage:
- Niacin: 25-50 mg (flush forma)
- Lion's Mane: 50-200 mg extraktu
- P Azurescens: 30-70 mg sušených
Schedule:
Days 1-4: stack, Days 5-7: off
Combines three components to maximize neuroplastic benefits. Recommended for experienced microdosers only due to P. azurescens potency.
Detailed Schedule:
- Days 1-4: Take all three components together in morning
- Days 5-7: Complete break from all components
- Repeat cycle for 4 weeks
- Take 2-4 week break before next cycle
✨ Reported Effects
Mood Enhancement
Observational studies indicate small-to-medium improvements in positive affect and reductions in negative mood
Mental Health Support
Small-to-medium reductions in depression, anxiety, and stress symptoms
Enhanced Creativity
May enhance divergent thinking and originality of responses
Neuroplasticity Support
Promotes structural and functional neuroplasticity via 5-HT2A receptor activation
⚠️ Safety Information
EXTREME POTENCY WARNING: P. azurescens contains up to 1.78% psilocybin (dry weight)—approximately 3× more potent than P. cubensis. Use only 30-50mg for microdosing (vs. 100-150mg for P. cubensis). Milligram-accurate scales (0.001g) are essential.
WOOD LOVER'S PARALYSIS (WLP): This species is strongly associated with temporary paralysis or muscle weakness lasting up to 24 hours. This effect does NOT occur with P. cubensis.
ABSOLUTE CONTRAINDICATIONS: History of psychosis, schizophrenia, bipolar disorder, lithium use (seizure risk), MAOI use (serotonin syndrome risk), pregnancy/breastfeeding, uncontrolled cardiovascular conditions, minors.
RELATIVE CONTRAINDICATIONS: Family history of severe mental illness, current SSRI/SNRI use, significant unprocessed trauma, previous adverse psychedelic reactions.
🔬 Scientific Research
Current research findings and clinical studies.
Depression scores dropped from 22.8 (severe) to 8.7 (mild) at week 1 post-treatment. Effect size (Cohen's d = 2.5) was 4× larger than traditional antidepressants. First RCT demonstrating psilocybin efficacy for major depression.
All 19 patients showed decreased depression at 1 week; 47% met response criteria at 5 weeks. Decreased amygdala blood flow correlated with reduced symptoms. Increased resting-state connectivity within DMN post-treatment suggests neural "reset" mechanism.
78% clinical response for depression and 83% for anxiety at 6 months. Single high-dose session produced substantial, sustained decreases in depression, anxiety, and death anxiety. Effects attributed to mystical-type experiences.
Subjective effects more intense for active dose only for participants who correctly identified their condition. No evidence supporting enhanced well-being, creativity, or cognition vs. placebo. Conclusion: "Expectation underlies at least some anecdotal benefits."
⚖️ Legal Status
Current legal status in various jurisdictions. Always respect local laws.
| Jurisdiction | Status | Details |
|---|---|---|
|
United States
(1970) |
Schedule I - Illegal
|
Psilocybin classified as having "high abuse potential, no accepted medical use" under the Controlled Substances Act. Possession: up to 1 year; Distribution: up to 20 years. FDA has granted Breakthrough Therapy Designation for treatment-resistant depression. |
|
Oregon
(2020) |
Legal - Supervised Therapeutic Use (21+)
|
Oregon legalized supervised therapeutic use through Measure 109 (2020). Implementation began June 2023. As of 2025: 31 licensed service centers, 356 licensed facilitators, ~8,000 clients served with only 5 emergency incidents. Sessions cost ~$1,000+ (not covered by insurance). P. azurescens grows naturally in Oregon; licensed manufacturers may use any psilocybin-producing fungi. |
|
Netherlands
(2008) |
Mushrooms: Illegal; Truffles: Legal
|
P. azurescens fruiting bodies are illegal (mushroom ban 2008). P. azurescens does not form significant sclerotia, making it effectively prohibited. Legal market focuses on truffle-forming species. |
|
Czech Republic
(2025) |
Medical Use: Legal from January 1, 2026
|
Czech Republic became first EU country to legalize psilocybin-assisted therapy for treatment-resistant depression (signed July 22, 2025). Only synthetic psilocybin permitted; administered in certified psychiatric clinics with 2 qualified therapists; maximum 75mg/month. 68% of Czechs support doctor-prescribed psychedelic therapy. Natural mushrooms including P. azurescens remain prohibited outside small-quantity decriminalization. |
|
Canada
(1974) |
Schedule III - Illegal with Medical Exemptions
|
Access via Section 56(1) exemptions (case-by-case approval from Health Canada) and Special Access Program (practitioners request for serious conditions). ~57 psilocybin dispensaries operate across 15 cities with uneven enforcement. |
|
United Kingdom
(1971) |
Class A Drug - Illegal
|
Same category as heroin and cocaine. Possession: up to 7 years imprisonment. Schedule 1 status requires Home Office license for research, creating significant barriers. Spores remain legal; germinating them is illegal production. |
👤 Key Figures
Notable figures associated with the research and history of this substance.
Gastón Guzmán
Mycologist, taxonomist
Authored major taxonomic works on the Psilocybe genus.
Paul Stamets
Mycologist, author, entrepreneur
First formally described P. azurescens (1995, with Gartz); discovered multiple Psilocybe species; author of "Psilocybin Mushrooms of the World"; founded Fungi Perfecti; developed Stamets Stack protocol; received National Mycologist Award and Gordon Wasson Award; character in Star Trek: Discovery inspired by him; species Psilocybe stametsii named in his honor (2023).
Roger Heim
Mycologist
Co-authored early scientific studies on psilocybin mushrooms and advanced classification of the genus.
Jochen Gartz
German chemist and mycologist
Co-author of P. azurescens description (1995); discovered aeruginascin; pioneered "entourage effect" research; conducted extensive chemical analysis confirming P. azurescens as among the most potent species; confirmed baeocystin is active as a psychedelic; co-discovered Psilocybe germanica (2015).
James Fadiman, Ph.D.
Psychologist, "Father of Microdosing"
Developed the Fadiman Microdosing Protocol; first to systematically collect microdosing reports (1,850+ from 30 countries); co-published first academic microdosing paper (2019); author of "The Psychedelic Explorer's Guide" (2011)—first book publication on microdosing.
Albert Hofmann
Chemist
Isolated psilocybin and psilocin, enabling scientific study of Psilocybe species.
Roland R. Griffiths, Ph.D.
Psychopharmacologist, Johns Hopkins professor (50+ years)
Founded Johns Hopkins Center for Psychedelic Research (2019); published landmark 2006 study reigniting psychedelic research renaissance; 2020 JAMA Psychiatry study showing psilocybin efficacy for depression; 400+ journal articles; legacy includes $24 million endowed professorship.
Robin Carhart-Harris, Ph.D.
Neuroscientist, UCSF professor
Founded Centre for Psychedelic Research at Imperial College London; pioneered brain imaging studies of psychedelic states; demonstrated DMN disruption correlates with therapeutic effects; developed "entropic brain hypothesis"; first to legally test LSD on volunteers in 40 years.
📚 Scientific Research
Erowid P. azurescens Experiences
User experience reports with P. azurescens
https://erowid.org/experiences/subs/exp_Mushrooms_P_azurescens_General.shtmlJohns Hopkins Center for Psychedelic Research
Leading psilocybin research institution
https://hopkinspsychedelic.org/MAPS - Psilocybin Resources
Multidisciplinary Association for Psychedelic Studies
https://maps.org/tag/psilocybin/Paul Stamets
Resources from the mycologist who formally described P. azurescens
https://paulstamets.com/❓ FAQ
**How long does onset take?**
Effects typically begin 20-60 minutes after oral ingestion, with faster onset (10-20 minutes) when consumed as tea. Peak effects occur 1-3 hours after ingestion and total duration is 4-6 hours, though P. azurescens experiences may extend to 8-10 hours due to higher potency.
**How should P. azurescens be stored?**
Store completely dried material (cracker-dry) in an airtight container with desiccant in a cool, dark, dry location. Refrigeration is acceptable if well-sealed against moisture. Properly stored, dried mushrooms maintain potency for 6-12 months, though some degradation occurs over time. Ground powder degrades faster than whole specimens.
**Why is P. azurescens more potent than other species?**
P. azurescens produces exceptionally high concentrations of the psilocybin biosynthesis pathway enzymes. The species also contains unusually high baeocystin levels (up to 0.4%), which may contribute to its effects. Genetic and environmental factors of its native Pacific Northwest coastal habitat likely play roles that are not fully understood.
**Can P. azurescens be combined with supplements like lion's mane?**
The "Stamets Stack" combines psilocybin with lion's mane and niacin. While some observational data suggests potential benefits (Rootman et al. 2022 found improved psychomotor performance in adults over 55), clinical evidence is limited. Lion's mane has mild MAOI properties—theoretical interaction potential exists. Complete a basic psilocybin-only cycle before adding supplements.
**How should dosages be adjusted from P. cubensis?**
Due to P. azurescens' approximately 3× higher potency, use roughly **one-third** of typical P. cubensis doses:
- P. cubensis microdose: 100-300mg → P. azurescens: **30-100mg**
- This requires milligram-accurate scales (0.001g precision recommended)
- Always start at the lowest end and titrate up slowly over multiple sessions
**How can quality be assessed?**
Quality specimens are completely dry (cracker-crisp), free of mold or off-odors, and show characteristic bluish bruising. Material should be homogeneous in appearance. Given potency variability, always treat each batch as potentially more potent than expected. Wild-harvested specimens carry identification and contamination risks—expert identification is essential.
Important Legal Notice
⚠️ Personal Responsibility
You use this application entirely at your own risk and responsibility. MicrodosingDiary is only a tool for recording personal experiences.
🚫 Not a Medical Service
This application IS NOT a medical tool, does not provide medical advice, does not diagnose or treat any conditions. Always consult a qualified physician.
⚖️ Legislation and Laws
Many substances used for microdosing are illegal in many countries. Users are fully responsible for complying with local laws. The application does not support or promote illegal activity.
❌ No Guarantees
We provide no guarantees regarding results, safety or efficacy of microdosing. All information is for informational purposes only.
🔞 Age Restriction
Application is intended only for persons over 18 years of age. By using the application you confirm that you are an adult.
🔒 Data Privacy
Your data is private and encrypted. We never share it with third parties without your consent. Application is for personal use only.
By using this application you accept all the above risks and waive any claims against the application operator.